Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Braveheart Inv Group (AIM:BRH) Operational update
Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
Abingdon Health PLC (AIM:ABDX) Award of Options under new LTIP Scheme
York, U.K. 19 December 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces the establishment of a new Long Term Incentive Plan
Abingdon Health PLC (AIM:ABDX) Preliminary Results
York, U.K. 24 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces its preliminary results for the year ended
Avacta Group PLC (AIM:AVCT) Avacta to Present at Theranostics FAP Summit
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) Proposed acquisition of Launch Diagnostics
Launch Diagnostics is a leading independent distributor in the UK in-vitro diagnostics (IVD) market
Abingdon Health PLC (AIM:ABDX) Further re. Outcome of Judicial Review
All grounds were dismissed, including the claim of state aid, apparent bias and national preference
Abingdon Health PLC (AIM:ABDX) Outcome of Judicial Review – All claims brought by GLP dismissed
York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, notes the judgement by Mr Justice Waksman in
Abingdon Health PLC (AIM:ABDX) Judicial Review – judgement expected
York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high-quality and effective rapid tests, notes that a judgement in relation to the
Avacta Group PLC (AIM:AVCT) Phase I study of AVA6000 advances to fourth cohort
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Abingdon Health PLC (AIM:ABDX) Supply agreement for Abingdon COVID-19 tests
Purchase of 10m Abingdon Health Simply Test COVID-19 antigen tests; subject to Taiwan FDA approval of test